Avecia, a part of Nitto Denko Inc.,^[1] is a private biotechnology company focused on the development and manufacture of novel medicines using biotechnology techniques. Avecia operates as a contract manufacturing organization (CMO), specializing in oligonucleotide production.^{[citation needed]}

Avecia has two US FDA-audited facilities, one near Boston, MA, and the second in Cincinnati, OH. The combined capacity of these two sites allows Avecia to handle oligonucleotide programs from the pre-clinical through commercial stages. In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.^{[citation needed]}